HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. - Wikidata - awgldk - TriplyDB

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.

http://www.wikidata.org/entity/Q51961251

about

Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV Long-term efficacy and safety of human papillomavirus vaccination "Knowledge and attitudes of Spanish adolescent girls towards human papillomavirus infection: where to intervene to improve vaccination coverage".Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.Integrating clinical, community, and policy perspectives on human papillomavirus vaccination Alternative dosage schedules with HPV virus-like particle vaccines.HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future.Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity Human papillomavirus 16 (HPV 16) and HPV 18 antibody responses measured by pseudovirus neutralization and competitive Luminex assays in a two- versus three-dose HPV vaccine trial.Prevention of cancer by prophylactic human papillomavirus vaccines.Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test.Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection.External genital human papillomavirus prevalence and associated factors among heterosexual men on 5 continents Prevalence of and risk factors for human papillomavirus (HPV) infection among HIV-seronegative men who have sex with men Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age.Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence.Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer Construction and characterisation of a recombinant fowlpox virus that expresses the human papilloma virus L1 protein.A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection.Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine.Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine.Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.A review of clinical trials of human papillomavirus prophylactic vaccines.Identification of B cell epitopes reactive to human papillomavirus type-16L1- derived peptides.Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.Is vaccine type seropositivity a marker for human papillomavirus vaccination? National Health and Nutrition Examination Survey, 2003-2010.Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids Human papillomavirus vaccination in HIV-infected women: need for increased coverage.Immunogenicity of quadrivalent HPV and combined hepatitis A and B vaccine when co-administered or administered one month apart to 9-10 year-old girls according to 0-6 month schedule.Evaluation of the immunogenicity of the quadrivalent HPV vaccine using 2 versus 3 doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes.Less than 3 doses of the HPV vaccine - Review of efficacy against virological and disease end points.An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girls Norovirus vaccine against experimental human Norwalk Virus illness.A quadrivalent HPV vaccine induces humoral and cellular immune responses in WHIM immunodeficiency syndrome.Qualitative responses to a national physician survey on HPV vaccination Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses.Currently approved prophylactic HPV vaccines.Does the HPV vaccination programme have implications for cervical screening programmes in the UK?

P2860

Q26783973-6F5FC8A9-B73C-4D30-919B-DDA29F555EFB Q28081156-8BDB7274-654A-43AB-A10C-92F9FDBFECC4 Q33772320-702AA2C1-B855-4516-8864-AC4F730BB1BB Q33856453-F3E0C018-3A7C-46CE-B0F4-1FC1CF5AE517 Q34078572-84440A4C-326C-4A6E-A478-112C4C9A2625 Q34102466-6DB6A3FE-BFAA-44FD-B339-D29747B8478D Q34335370-9E1A1B05-0136-49B4-9036-6E536458D734 Q34352416-53D74BDD-0E61-46A1-9E01-3837FAB2A198 Q34738944-C0CA2332-C2F4-4B53-B57D-34E78C086163 Q34762053-E9E46C82-6596-4E52-8E18-BB41C34B47F3 Q34765264-5F9943D8-15AF-481B-AE1F-23E414EFE19D Q34786808-10318555-D73D-48D9-B238-E1EA34D1E828 Q34910428-E8BE879D-9052-4225-AFF1-09C9904FC775 Q34910475-FE465608-6175-48A5-B1D7-DFC66DEFE906 Q35008398-F0FA17F7-1A13-4B6E-9DCA-4319D685A364 Q35108338-849DBA78-14F0-4B09-AFE9-BBADED082493 Q35121855-6B606079-C62D-470A-906C-E1EEF2C19DAE Q35258843-3B692BDA-54B2-416C-9786-5BE351BC02FB Q35595612-8FE3C54A-0FE3-4E7A-AF18-8C30F18D2A10 Q35599310-24CFF559-5806-43FF-A015-897B7F50FC4E Q35757389-D8CAA80C-8D10-4A39-B43D-BAAFFEC0A3DA Q35901974-299E1D2D-3A14-4FB3-8689-330FBFC1057F Q35918834-FC655F7D-09BF-4A1B-BA6F-76239458FFD5 Q36259403-8C93983F-2036-41D7-BD28-C4FAC5F0373B Q36295220-D3D4F79B-E68F-488C-91B9-F4B552C943AA Q36305499-F73FAC69-2B4E-45D5-AAE0-2E1E80FF99DE Q36318591-F7F887B4-53F4-4B5E-A03F-1F87291231A5 Q36486823-F6D9C4C6-3C68-4886-BECD-88DB0375DBE1 Q36750553-AAF9FA6A-706A-44BF-B652-2D86B12EBF64 Q36780952-88E6BB0B-F523-4A14-A260-A3591A2FFC1F Q36978399-BB8E96B8-DEE8-461C-ACE7-E9C71E896E17 Q37130168-6EBCD34C-68A7-4CF6-B815-05F51C169486 Q37135074-7E517619-B64A-4073-B1DB-8513686CBA12 Q37135276-0520CE9C-3751-412C-998A-21D6FB8B8206 Q37144052-6ECC8D69-1533-43C6-A7A1-0387B2D61B32 Q37219730-A92B7D75-2D4F-430A-A3F7-D17330389761 Q37309804-E1EC4D7A-FAF2-4C5C-AF04-2FBE9DE50744 Q37612161-B6ABFC29-0CEB-4F8D-AF4B-7BF98173FCF5 Q37640113-2A449BAD-17FA-4AE2-9E1F-7446CF4C617A Q37709718-EB10AD6B-05DF-44AD-A5F8-0ECB3D6B90CE

P2860

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.

http://www.wikidata.org/entity/Q51961251

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

HPV antibody levels and clinic ...... ctic quadrivalent HPV vaccine.

@en

HPV antibody levels and clinic ...... ctic quadrivalent HPV vaccine.

@nl

type

label

HPV antibody levels and clinic ...... ctic quadrivalent HPV vaccine.

@en

HPV antibody levels and clinic ...... ctic quadrivalent HPV vaccine.

@nl

prefLabel

HPV antibody levels and clinic ...... ctic quadrivalent HPV vaccine.

@en

HPV antibody levels and clinic ...... ctic quadrivalent HPV vaccine.

@nl

P1433

Q51961251-C8259670-FA90-4DC7-B362-DE9693492A04

P1476

Q51961251-CF348E71-96BB-4ACD-AD8B-E595BD018773

P2093

Q51961251-04949F76-8861-4D24-8024-E1511108A901

Q51961251-07FB9462-FB1A-4A48-9BD3-EC74AB1F4CAF

Q51961251-32697546-7559-4C39-979D-DA2832A30E39

Q51961251-327F0636-D697-4972-8788-508CF2F7CFEC

Q51961251-3A68BCDE-ACBC-4447-8015-876DCA2B5F3B

Q51961251-42743823-DFD2-4862-873B-E85D4085E7F6

Q51961251-60B21C66-ACF3-481A-A858-832DE0FF3A2D

Q51961251-619AF746-1CE1-49E1-9BE6-DBA989F66C6C

Q51961251-61F192D3-FC61-4BB7-A0B3-0378D7549A4C

Q51961251-6965E2A2-8D0C-4B41-8CD6-73F21C9AF007

P304

Q51961251-25875C7A-78BF-40B3-B0D4-BC214441CF9D

P31

Q51961251-644A4932-5A6F-46E7-B366-2381E308D060

P356

Q51961251-EB9CBA53-C3CB-4FD8-A93A-72D34FA6AB2A

P407

Q51961251-9D20BD3A-61A6-4E84-BCD9-C885D366A225

P433

Q51961251-1CCF0017-CAA0-482C-A3F4-015B67955F0A

P478

Q51961251-B5DC1CBD-C8F3-4960-BFAD-58BBDF2C78C1

P50

Q51961251-319AA4BD-6EE3-43E6-8C80-9939021DDDA0

Q51961251-7F94ABA1-FC89-4B3D-B7CD-E66D8F1DBC42

Q51961251-83FF71BF-FCE4-4F63-98E0-6410495276A5

Q51961251-916F4C81-2E44-4A03-A768-C52FFC838FC5

Q51961251-98225AC7-0DBC-4EF1-BF13-4788EC61F556

Q51961251-B8D5511B-A3A2-4119-B89D-0C478EF6AA98

P577

Q51961251-08DFCD8B-5FAA-4371-96FB-D9B518FF1F4E

P5875

Q51961251-2AEB4084-888A-4E9A-8207-4A9549833FC0

P698

Q51961251-6650013B-A10C-4EE9-A25E-F3330C75159B

P921

Q51961251-E08A3585-FF16-4967-9FAA-587BB333D349

P356

J.VACCINE.2008.09.073

P1433

P1476

HPV antibody levels and clinic ...... ctic quadrivalent HPV vaccine.

@en

P2093

Amha Tadesse

http://www.w3.org/2001/XMLSchema#string

Daron G Ferris

http://www.w3.org/2001/XMLSchema#string

Darron R Brown

http://www.w3.org/2001/XMLSchema#string

Eliav Barr

http://www.w3.org/2001/XMLSchema#string

Elmar A Joura

http://www.w3.org/2001/XMLSchema#string

Eng Hseon Tay

http://www.w3.org/2001/XMLSchema#string

Evan R Myers

http://www.w3.org/2001/XMLSchema#string

Frank J Taddeo

http://www.w3.org/2001/XMLSchema#string

Gonzalo Perez

http://www.w3.org/2001/XMLSchema#string

Grace W K Tang

http://www.w3.org/2001/XMLSchema#string

P304

6844-6851

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2008.09.073

http://www.w3.org/2001/XMLSchema#string

P407

P433

52

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

Susanne Krüger Kjaer

Christine C Roberts

Cosette M Wheeler

P577

2008-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23393705

http://www.w3.org/2001/XMLSchema#string

P698

18930097

http://www.w3.org/2001/XMLSchema#string

P921